For research use only. Not for therapeutic Use.
Sitravatinib(CAT: I000466) is a novel small molecule inhibitor that targets multiple receptor tyrosine kinases (RTKs) involved in driving sarcoma cell growth. RTKs are a family of cell surface receptors that play a critical role in various cellular processes, including cell growth, proliferation, and survival. By inhibiting these RTKs, sitravatinib disrupts the signaling pathways that promote the growth of sarcoma cells. This targeted approach makes sitravatinib a potential therapeutic option for the treatment of sarcomas, a diverse group of malignant tumors arising from mesenchymal tissues.
Catalog Number | I000466 |
CAS Number | 1123837-84-2 |
Synonyms | MGCD516; MG-516 |
Molecular Formula | C33H29F2N5O4S |
Purity | ≥95% |
Target | RTK inhibitor |
Solubility | DMSO ≥ 32 mg/mL |
Storage | Store at -20°C |
IUPAC Name | 1-N'-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
InChI | InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42) |
InChIKey | WLAVZAAODLTUSW-UHFFFAOYSA-N |
SMILES | COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F |
Reference | 1:Oncotarget. 2016 Jan 26;7(4):4093-109. doi: 10.18632/oncotarget.6547. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.Patwardhan PP,Ivy KS,Musi E,de Stanchina E,Schwartz GK, PMID: 26675259 PMCID: PMC4826192 DOI: 10.18632/oncotarget.6547<br /> |